From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.

ABSTRACT: Migraine is a neurovascular disorder that can be debilitating for individuals and society. Current research focuses on finding effective analgesics and management strategies for migraines by targeting specific receptors and neuropeptides. Nonetheless, newly approved calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have a 50% responder rate ranging from 27 to 71.0%, whereas CGRP receptor inhibitors have a 50% responder rate ranging from 56 to 71%. To address the need for novel therapeutic targets, researchers are exploring the potential of another secretin family peptide, pituitary adenylate cyclase-activating polypeptide (PACAP), as a ground-breaking treatment avenue for migraine. Preclinical models have revealed how PACAP affects the trigeminal system, which is implicat

SUBMITTER: Tanaka M 

PROVIDER: S-EPMC10670698 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature